Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Advies over sluisplaatsing nogapendekin alfa inbakicept en aumolertinib
feb 2026 | Longoncologie, Uro-oncologie